Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-02-16

Clinical Trial Update: Study Comparing Treatment With Alluzience vs Reconstituted Toxin [Phase 4]

View source ↗

Summary

A phase 4 trial comparing Alluzience with reconstituted toxin for treatment of glabellar frown lines has completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alluzience

Snippet

Sponsor: Galderma R&D | Conditions: Glabellar Frown Lines | Phase 4 | Status: COMPLETED | Results posted: 2024-02-16